Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced platelet dysfunction and cardiopulmonary bypass.

E W Muriithi1, P R Belcher, S P Day

  • 1Department of Cardiac Surgery, University of Glasgow, Royal Infirmary, Scotland. e.w.muriithi@clinmed.gla.ac.uk

The Annals of Thoracic Surgery
|July 13, 2000
PubMed
Summary

Heparin in cardiopulmonary bypass indirectly inhibits platelet aggregation through plasma changes. This delayed effect is transferable to normal platelets in vitro, impacting blood clotting during surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mathematical representation and nonlinear modelling of the Wheatley mitral valve.

Medical engineering & physics·2025
Same author

Regularization of a Mathematical Model of the Wheatley Heart Valve.

Journal of biomechanical engineering·2022
Same author

A Mathematical Representation of the Wheatley Heart Valve.

Journal of biomechanical engineering·2021
Same author

Percutaneous heart valves; past, present and future.

Perfusion·2014
Same author

A new approach to scoring systems to improve identification of acute medical admissions that will require critical care.

Scottish medical journal·2011
Same author

Formation of PGD(2) Contributes to the Anti-aggregatory Efficacy of ZD1542, a Thromboxane A(2) Synthase Inhibitor and TP Receptor Antagonist, in Human Whole Blood.

Platelets·2010

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Surgical Research

Background:

  • Cardiopulmonary bypass (CPB) is linked to impaired platelet macroaggregation.
  • Heparin administration before CPB can cause platelet dysfunction.
  • In vitro heparinization of whole blood does not impair macroaggregation, suggesting an indirect mechanism.

Purpose of the Study:

  • To investigate the mechanism of heparin-induced platelet dysfunction during CPB.
  • To determine if plasma changes induced by in vivo heparinization affect platelet macroaggregation.
  • To assess the delayed and transferable nature of this inhibition.

Main Methods:

  • Whole blood impedance aggregometry was used to measure platelet macroaggregation in response to collagen.
  • Blood samples were obtained from patients undergoing CPB and healthy volunteers.

Related Experiment Videos

  • Platelet-poor plasma from CPB patients at various stages was used to dilute blood from volunteers and assess macroaggregation.

    • Main Results:

    • Platelet-poor plasma obtained after heparinization or during CPB significantly reduced platelet macroaggregation compared to pre-heparinization.
    • This inhibitory effect was transferable to normal platelets from volunteers.
    • The inhibitory effect on macroaggregation in post-heparinization blood increased over time, showing a delayed onset.

    Conclusions:

    • In vivo heparinization induces plasma alterations that inhibit platelet macroaggregation.
    • This inhibition is indirect, delayed, and can be transferred in vitro to normal platelets.
    • Understanding these plasma-mediated effects is crucial for managing platelet function during CPB.